Kết quả tìm kiếm - Heidrun Bosch‐Traberg

  • Đang hiển thị 1 - 6 kết quả của 6
Tinh chỉnh kết quả
  1. 1
    Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

    Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial Bằng Yutaka Seino, Shizuka Kaneko, Shuichi Fukuda, Takeshi Osonoi, Toshihiko Shiraiwa, Keiji Nishijima, Heidrun Bosch‐Traberg, Kohei Kaku

    Được phát hành 2015
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial

    Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial Bằng Katherine R. Tuttle, Stephen C. Bain, Heidrun Bosch‐Traberg, Kamlesh Khunti, Søren Rasmussen, Ekaterina Sokareva, David Z. Cherney

    Được phát hành 2024
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney fun... Bằng Katherine R. Tuttle, Heidrun Bosch‐Traberg, David Z.I. Cherney, Samy Hadjadj, Jack Lawson, Ofri Mosenzon, Søren Rasmussen, Stephen C. Bain

    Được phát hành 2023
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

    Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Cl... Bằng Melanie J. Davies, Stephen C. Bain, Stephen L. Atkin, Peter Rossing, David A. Scott, Минара Шамхаловна Шамхалова, Heidrun Bosch‐Traberg, Annika Syrén, Guillermo E. Umpierrez

    Được phát hành 2015
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

    The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease Bằng Peter Rossing, Florian M.M. Baeres, George L. Bakris, Heidrun Bosch‐Traberg, Mette Gislum, Stephen Gough, Thomas Idorn, Jack Lawson, Kenneth W. Mahaffey, Johannes F.E. Mann, Henriette Mersebach, Vlado Perkovic, Katherine R. Tuttle, Richard Pratley

    Được phát hành 2023
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

    Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial Bằng Johannes F.E. Mann, Peter Rossing, George L. Bakris, Nicolas Belmar, Heidrun Bosch‐Traberg, Robert S. Busch, David M. Charytan, Samy Hadjadj, Pieter Gillard, José Luis Górriz, Thomas Idorn, Linong Ji, Kenneth W. Mahaffey, Vlado Perkovic, Søren Rasmussen, Roland E. Schmieder, Richard E. Pratley, Katherine R. Tuttle

    Được phát hành 2024
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: